Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS005 in Active Ankylosing Spondylitis
NCT06250062Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of roconkibart in ankylosing spondylitis (AS), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jan 2024; status: completed.
02
Drugs
roconkibart
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT06250062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250062.